KEYNOTE-689: A Phase 3 Study of Neoadjuvant and Adjuvant Pembrolizumab Plus Standard of Care (SOC) in Resectable, Locally Advanced (LA) Head and Neck Squamous Cell Carcinoma (HNSCC)

Arkadiy Klochikhin,Robert I. Haddad,Amichay Meirovitz,Sufia Safina,Irene Brana,Christophe Le Tourneau,Ravindra Uppaluri,Nancy Y. Lee,Ezra E.W. Cohen,Rebecca Chernock,William Westra,Hong Liu,Burak Gumuscu,Kimberly Benjamin,Douglas Adkins

European Journal of Surgical Oncology（2023）

引用 0|浏览51

暂无评分

摘要

Introduction: The randomized, open-label, phase 3 KEYNOTE-689 trial (NCT03765918) is designed to evaluate neoadjuvant pembrolizumab and adjuvant pembrolizumab plus SOC in previously untreated LA HNSCC.

查看译文

关键词

neck squamous cell carcinoma,neoadjuvant pembrolizumab plus standard,cell carcinoma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要